

# Perceived diagnostic delay and cancer-related distress: a cross-sectional study of patients with colorectal cancer

Anne Miles<sup>1\*</sup>, Paula L. McClements<sup>2</sup>, Robert J.C. Steele<sup>3</sup>, Claudia Redeker<sup>1</sup>, Nick Sevdalis<sup>4</sup> and Jane Wardle<sup>5</sup>

<sup>1</sup>Department of Psychological Sciences, Birkbeck, University of London, London, UK

<sup>2</sup>Information Services Division, NHS National Services Scotland, Edinburgh, UK

<sup>3</sup>Centre for Research into Cancer Prevention and Screening, Cancer Division, Medical Research Institute, Ninewells Medical School, Dundee, UK

<sup>4</sup>Centre for Implementation Science, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

<sup>5</sup>Health Behaviour Research Centre, Institute of Epidemiology and Public Health, University College London, London, UK

\*Correspondence to:

Department of Psychological Sciences, Birkbeck, University of London, Malet Street, London WC1E 7HX, UK. E-mail: ae.miles@bbk.ac.uk

## Abstract

**Objective:** This study aimed to examine the effect of perceived diagnostic delay on cancer-related distress and determine whether fear of cancer-recurrence and quality of life mediate this relationship.

**Methods:** Cross-sectional study in which 311 colorectal cancer (CRC) survivors in Scotland completed a survey, which included questions on cancer-related distress (IES-R), perceived diagnostic delay, quality of life (trial outcome index of the FACT-C: FACT-C TOI) and fear of cancer recurrence. Fifteen patients withheld consent to data matching with medical records, leaving a sample size of 296. Participants were an average of 69 years old (range 56 to 81) and between 3.5 and 12 years post-diagnosis. Multiple regressions were used to test predictors of distress and regression and bootstrapping to test for mediation.

**Results:** Perceived diagnostic delay was correlated with higher cancer-related distress, while objective markers of diagnostic delay (disease stage at diagnosis and treatment received) were not. Some of the relationship between perceived diagnostic delay and cancer-related distress was mediated by quality of life, but not by fear of cancer recurrence.

**Conclusions:** Perceived diagnostic delay was associated with higher cancer-related distress among CRC survivors. While poorer quality of life partly explained such associations, fear of cancer recurrence, stage at diagnosis and treatment did not. The exact features of diagnostic delay that are associated with cancer-related distress remain unclear. Future research should examine the experiences patients go through prior to diagnosis that may increase distress, in an effort to improve our understanding of the factors affecting emotional wellbeing among CRC survivors.

Copyright © 2016 John Wiley & Sons, Ltd.

Received: 15 July 2015

Revised: 25 November 2015

Accepted: 15 January 2016

## Background

Earlier stage at diagnosis is strongly associated with improvements in cancer survival [1]. Consequently, a number of initiatives have been introduced to try and reduce diagnostic delay among both patients [2] and healthcare providers [3], with the emphasis on improving prognosis. However, little research has examined the psychological benefits of reducing diagnostic delay. A cancer diagnosis is always distressing, but the impact may be even worse if patients believe the route to diagnosis has been inefficient.

There are a number of reasons to expect adverse psychological effects as a result of diagnostic delay. Qualitative research into the experience of having colorectal cancer (CRC) diagnosed at screening found many people described the diagnosis as relatively untraumatic, because of the absence of a period of symptoms and associated worry about a potential cancer diagnosis and simpler

treatment, which often involved surgery alone [4]. While receiving the actual diagnosis has been identified as the most stressful aspect, periods of waiting are also high on the list [5], and research in lung cancer patients found that a more rapid diagnosis was associated with less distress [6].

The need to identify and manage distress among cancer survivors is increasingly recognised, with calls to integrate psychological assessment into routine care [7]. Psychological difficulties following a cancer diagnosis include depression, anxiety and stress-related responses including post-traumatic stress disorder (PTSD). Such difficulties are often comorbid among cancer survivors [8,9]. While symptoms of full-PTSD are typically less frequent than those of depression and anxiety, they are found in a significant minority of cancer survivors (e.g. [10–12]), with much higher rates of sub-threshold symptoms (e.g. 33% [5,12]). Consequently, there have been specific calls for more research into factors that can increase vulnerability to cancer-related distress

[10]. Symptoms of trauma comprise avoidance, intrusive thoughts and hyper-arousal and reflect subjective distress in relation to a traumatic event. The presence of a specific cluster of symptoms or symptom intensity (indexed by cut-off scores) can be used to identify PTSD. While a number of demographic and clinical correlates of cancer-related distress have been identified, with higher cancer-related distress among younger people [13,14], a more recent diagnosis [15], and patients with more advanced disease [10]; the effect of diagnostic delay has received little attention. One exception is a study, which found higher distress among people with longer objective markers of delay in diagnosis and treatment [16].

There are a number of ways in which perceived delay could affect the patient. Patients may be concerned that any delay in diagnosis has resulted in more advanced disease and necessitated more toxic or invasive treatments, both of which are associated with higher distress [10,17]. In addition, the belief that there has been a delay in diagnosis could also increase fears of cancer recurrence and raise concerns that the cancer and its treatment have had an unnecessarily adverse effect on the individual's quality of life.

The cognitive model of persistent PTSD forwarded by Ehlers and Clark [18] proposes that persistent PTSD occurs only if 'individuals process the trauma in a way that leads to a sense of serious, current threat', and that this can come from 'excessively negative appraisals of the trauma and/or its sequelae.' Fear of cancer recurrence (FCR) refers to fear that cancer could come back, or progress, in either the same place or in another part of the body, and researchers have argued that FCR provides a sense of current serious threat and can hence lead to post-traumatic symptomatology [19]. Consistent with this view, previous research has documented strong associations between FCR and cancer-related distress [19,20]. It can also be argued that excessively negative appraisals of the sequelae of cancer can be indexed by patients' assessment of their quality of life. Quality of life is a multidimensional construct, comprising self-reported physical, functional, social/family and emotional wellbeing [21]. Previous research has shown that PTSD responses are associated with both poor social functioning and reduced physical functioning [11,22–24]. Hence, according to this model, and previous research findings, both FCR and quality of life could mediate associations between diagnostic delay and distress.

The present study aimed to examine the predictors of cancer-related distress among patients with CRC and test mediational pathways between perceived delay and cancer-related distress. We hypothesised that:

- 1 Cancer-related distress would be higher among CRC patients who perceived there had been delay in their diagnosis.

- 2 Fear of recurrence and quality of life would contribute to explaining associations between perceived diagnostic delay and cancer-related distress, over and above any contribution of stage at diagnosis and treatment received.

## Ethical approval

Ethical approval was obtained from Riverside Research Ethics Committee (reference number: 09/H0706/41). Approval for identifying potential participants via database linkage was granted by the NHS National Services Scotland Privacy Advisory Committee and the NHS Scotland Community Health Index Advisory Group.

## Materials and methods

### Design and setting

Cross-sectional study examining people diagnosed with CRC in Scotland between 2000 and 2008.

### Participants and recruitment

Potential participants were identified by linking the Scottish Cancer Registry and Scottish Colorectal Cancer Screening Pilot databases by their Community Health Index (CHI) number. The CHI database was used to identify patient and general practitioner (GP) details. The CHI is a unique identifier for individuals registered at general practices in Scotland and contains information on date of birth and gender. Practitioner Services Division at NHS National Services Scotland (NSS) co-ordinated patient contact via their GPs. Patients identified as deceased, or as having moved from the area, were excluded. Practitioner Services Division was given template letters for GPs and patients; they added GP and patient details and forwarded the letters to the GPs to pass on to eligible patients. This process was approved by the Riverside Research Ethics Committee, NHS NSS Privacy Advisory Committee and the NHS NSS Community Health Index Advisory Committee. GPs were asked to confirm the diagnosis of CRC and exclude patients who were deceased or terminally ill, unable to speak or read English or lacked the capacity to take some or all decisions for themselves because of mental disorder or inability to communicate. The first survey was sent to GP practices in June 2012 and the reminder survey for non-responders in September 2012. Patients had their CRC diagnosed at FOBt screening or outside of screening (either following a negative screening result or because they lived outside the areas of the Scottish Pilot). Differences in psychological outcomes in relation to diagnostic pathway have been reported elsewhere [25].

### Measures

Age, gender, Scottish Index of Multiple Deprivation [26], Dukes' stage at diagnosis, treatment received (surgery,

radiotherapy and chemotherapy) and time since diagnosis (in years) were supplied by NHS NSS with patient consent. All other variables were measured in the questionnaire. Employment status was assessed, and ethnicity was measured using questions from the Scottish Census 2011 with the addition of a 'Prefer not to say' response option. Co-morbidities were self-reported (heart or vascular disease, diabetes, epilepsy, stroke, arthritis, asthma, mental or emotional disorder, cancer (other than bowel cancer) and any other illness (open-ended)) and combined into a single variable 'comorbidity' (Yes/No). Cancer recurrence was assessed with the item: 'Has the cancer come back (recurred) since your first treatment?', response options: 'yes', 'no', 'I don't know / can't remember'. 'If yes, in what part of the body? (open-ended).'

The main outcome variable was current cancer-related distress, measured by the Revised Impact of Events Scale (IES-R) [27], which has three subscales: intrusion, avoidance and hyperarousal, as well as a total score. The IES-R can be used to measure distress (range 0–88) or suspected presence of PTSD (scores of 33 or higher). The IES-R was chosen because it is one of the most commonly used measures of cancer-related distress [28], with scale items directly corresponding to 14 of the 17 symptoms of PTSD outlined in DSM-IV [29] (the DSM version in use at the time of the study). Participants were asked to indicate how they had been feeling during the past 7 days with respect to their cancer.

The main predictor was perceived diagnostic delay: 'Do you think your cancer could have been diagnosed sooner than it was' with response options: 'yes', 'not sure' and 'no' and was entered into analyses as an ordinal variable. Quality of life and FCR were potential mediators. Quality of life at the time of study participation (i.e. over the preceding seven days) was assessed using the FACT-C [30]. This is a 34-item questionnaire that generates four wellbeing subscales: physical, functional, social/family and emotional, which can be summed to form a general score (the FACT-G) allowing comparisons to be made across different cancers, and an additional CRC subscale which, along with the other subscales, forms a colorectal-cancer specific measure (the FACT-C). To reduce conceptual overlap with cancer-related distress, we used the Trial Outcome Index (FACT-C TOI), which sums the physical, functional and CRC subscales.

Fear of cancer recurrence at the time of the study was assessed using a four item scale [31] with the wording altered to ask about bowel cancer (the term commonly used for CRC in the UK) rather than breast: 'How often have you worried about getting bowel cancer again' 'How often have worries about getting bowel cancer again affected your mood', 'How often have worries about getting bowel cancer again affected your ability to carry out your daily activities' and 'How concerned were you about getting bowel cancer again.' Response options were: 'Not at all or rarely', 'sometimes', 'often' and 'a

lot'. Participants were asked to rate their concerns over the past month, and the scale showed good levels of internal reliability (Cronbach's  $\alpha=0.773$ ).

### Statistical analysis

Predictors of cancer-related distress were examined using linear and logistic regression. Potential mediators of the link between perceived diagnostic delay and cancer-related distress were assessed using the software Mplus 7.11, and the robust weighted least squares estimation technique [32].

### Response rate

GPs were sent research invitation letters for 675 patients, of whom 142 were not contacted (either because the patient met one or more exclusion criteria ( $n=70$ ) or the GP did not wish to participate in the research ( $n=72$ )), leaving 533 patients who were mailed a questionnaire (a response rate of 58.3%,  $N=311$ ). Fifteen withheld consent for data-matching to NSS, leaving 296 as the sample for analysis; a response rate of 55.5%.

### Missing data

Scores on the IES-R, FACT-C and FCR scales were only computed if patients had answered at least 50% of the items otherwise they were recorded as missing. Missing data were 5% or higher for Dukes' stage, receipt of radiotherapy, and the FACT-C TOI, but less than 5% for all the other variables (Table 1). The mediation analysis was conducted both with completed data and with data imputed for missing values.

## Results

### Background variables

Descriptive and clinical characteristics of the whole sample are shown in Table 1. The average age was 69 years, ranging from 56 to 81, consistent with the age of invitation to the Scottish CRC Screening Pilot (50–69) and time since diagnosis. Time since diagnosis ranged from 3.5 to 12 years. Half of the sample (49%) was men, almost all described their ethnicity as white (99%), and the majority were retired from work (75%). Participants were less deprived than the general population of Scotland, with over 20% in each of the higher quintiles.

### Predictor and outcome variables

Perceived diagnostic delay was significantly correlated with receiving chemotherapy ( $r=0.204$ ;  $p<0.001$ ) and radiotherapy ( $r=0.122$ ;  $p=0.044$ ). The correlation with Dukes' stage at diagnosis approached significance ( $r=0.120$ ;  $p=0.055$ ).

On the IES-R, 6% scored 33 or higher, indicating the likely presence of PTSD, consistent with other studies using symptom checklists where rates between 5–12% are reported [24]. Participants reported similar quality of life scores to other research on CRC patients [30] with levels equivalent to CRC survivors with no evidence of disease [33]. Cut-off scores for the FACT-G show 19% of the current sample reported poor quality of life [33] (Table 1). Clinical cut-off scores for FCR have not been developed [34], but average scores were low, with 13.1% of participants reporting an average score of two or more, and only 1.4% reporting an average score of three or more.

### Predictors of cancer-related distress

Average level of distress by perceived diagnostic delay showed a linear trend across the three points of the scale (no: 8.31; not sure: 11.49; yes: 13.78). When all variables that were significant in univariate analyses were entered into the model (age, gender, deprivation, comorbidities, time since diagnosis, FCR, FACT-C TOI, delay), only age, perceived diagnostic delay, FCR and FACT-C TOI scores remained significant predictors. Using suspected PTSD caseness as the outcome (yes/no), only perceived diagnostic delay and FACT-C TOI were significant predictors of cancer-related patient distress in multivariate analyses (Table 2).

### Mediation analysis

In order to test whether FCR or quality of life mediated the relationship between perceived diagnostic delay and cancer-related distress, variables that predicted cancer-related distress in multivariate analyses were entered into a model (Figure 1). Correlations between these variables are shown in Table 3. The product of regression coefficients (used to calculate indirect effects) often violates the assumption of a normal distribution, potentially leading to biased results, so bias-corrected bootstrapping ( $N = 5000$ ) was used to generate confidence intervals around the mediation analyses [35]. The sample size was sufficient to detect medium effect-size associations in mediational analyses [36]. As shown in Figure 1, quality of life (FACT-C TOI) mediated some of the relationship between perceived diagnostic delay and cancer-related distress, but there was no pathway from perceived diagnostic delay to distress via FCR. The model accounted for 54% of the variance in cancer-related distress. The indirect effect from perceived diagnostic delay to cancer-related distress via FACT-C TOI was significant (0.052, CIs: 0.001 to 0.103,  $p = 0.045$ ), as were the indirect effects between age and distress via both FCR ( $-0.105$ , CIs:  $-0.050$  to  $-0.160$ ,  $p < 0.001$ ) and FACT-C TOI ( $-0.057$ , CIs:  $-0.006$  to  $-0.109$ ,  $p = 0.029$ ). All indirect effects remained significant using imputed data. There was a strong correlation between FCR and FACT-C TOI.

**Table 1.** Demographic, clinical and psychological characteristics ( $N = 296$ )

	% (n)
Age when completed study	
50–59	4.4 (13)
60–69	49.3 (146)
70–79	44.6 (132)
80+	1.7 (5)
Gender	
Male	49.3 (146)
Female	50.7 (150)
Scottish index of multiple deprivation (fifths)	
1 (most deprived)	7.4 (22)
2	16.9 (50)
3	24.0 (71)
4	26.7 (79)
5 (least deprived)	24.0 (71)
Missing	1.0 (3)
Employment status	
Working (full-time, part-time or self-employed)	18.2 (54)
Retired	74.3 (220)
Other (home maker, students, unemployed or too ill to work/ disabled)	6.4 (19)
Missing	1.0 (3)
Ethnic group	
White	98.3 (291)
Non-white	1.0 (3)
Missing	0.7 (2)
Time since diagnosis (years)	
3 to 4.9	11.1 (33)
5 to 9.9	70.3 (208)
10+	18.6 (55)
Dukes' stage	
A	23.0 (68)
B	35.1 (104)
C	28.4 (84)
D	2.0 (6)
Missing	11.5 (34)
Surgery	
Yes	96.6 (286)
No	2.4 (7)
Missing	1.0 (3)
Radiotherapy	
Yes	12.5 (37)
No	80.4 (238)
Missing	7.1 (21)
Chemotherapy	
Yes	40.2 (119)
No	55.1 (163)
Missing	4.7 (14)
Comorbidities	
Yes	70 (208)
No	30 (88)
Reported cancer recurrence following first diagnosis (both related and unrelated to initial bowel cancer diagnosis)	
Yes	8.4 (25)
No	88.5 (262)
Don't know or can't remember	1.0 (3)
Missing	2.0 (6)
Perceived diagnostic delay	
Yes	26.7 (79)

*Continues*

Table 1. Continued

	% (n)
Not sure	13.9 (41)
No	58.4 (173)
Missing	1.0 (3)
Fear of cancer recurrence (1–4) mean (sd)	1.50 (0.54)Range: 1–4(n = 291)
Quality of life	
Overall quality of life (FACT-C total), mean (sd)	111.94 (17.21)Range: 41.10–136.00(n = 266)
Overall quality of life (FACT-G total), mean (sd)	89.8 (14.3)Range: 32.1 to 108.00(n = 267)
Proportion reporting low quality of life (FACT-G scores less than 78.8)	19.1 (51)(n = 267)
Physical, functional and colorectal subscales (FACT-C TOI) (0–84), mean (sd)	69.78 (12.72)Range: 14.17–84.00(n = 269)
Cancer-related distress (IES-R)	
Total score (0–88), mean (sd)	10.23 (13.19)Range: 0–80.20(n = 289)
Avoidance (0–32), mean (sd)	4.70 (5.76)(n = 289)
Hyper-arousal (0–28), mean (sd)	2.20 (4.11)(n = 289)
Intrusions (0–28), mean (sd)	3.34 (4.58)(n = 289)
Suspected PTSD caseness (participants scoring 33 or higher)	6 (17)

Sd, standard deviation; PTSD, post-traumatic stress disorder.

## Conclusions

In line with our predictions, we found that cancer-related distress was higher among cancer survivors who perceived diagnostic delay. However, neither disease stage at diagnosis nor treatment predicted distress, showing it was the subjective perception, rather than objective markers, of delay that was associated with adverse psychological outcomes. When examining predictors of likely presence or absence of PTSD, only perceived diagnostic delay and poorer quality of life were significant predictors in multivariate analyses, confirming the importance of exploring perceived delay in the context of cancer distress.

Mediation analysis showed that, in addition to a direct effect on cancer-related distress, perceived diagnostic delay also had an indirect effect via quality of life, but FCR,

although a significant predictor of distress, was not significantly associated with perceived delay. However, the study was underpowered to detect small mediation effects. The majority of participants were diagnosed over 5 years prior to study participation, and concerns about the effect of diagnostic delay on recurrence may have reduced, with the realisation that any delay had not proved fatal.

Consistent with previous research, we found that younger age was associated with higher levels of cancer-related distress [11]. Part of this association was mediated by greater FCR and poorer self-reported physical, functional and colorectal quality of life. Green *et al.* [5] have speculated that negative associations between age and distress may be due to the more unexpected nature of the diagnosis, and greater impact on both the patient's life and that of their family, due to work and care-giving commitments. An additional explanation is that older people may have developed greater resilience to stress [37]. Causes are likely to be multiple, but the present study confirms the need to be vigilant to the multiple cancer-related concerns that may exist among younger adults, including FCR and on-going symptomatology and functional impairment.

A strong association was also observed between FCR and physical functional and colorectal quality of life. Lee-Jones *et al.* [38] raise the possibility that FCR can lead to an increased focus on somatic symptoms. Similarly, the presence of bodily symptoms could promote fears of a recurrence and may explain the associations observed between these variables in the current study.

To our knowledge, this is the first study to compare the effect of perceived diagnostic delay on psychological outcomes in the context of CRC (see [39] for details of a study in progress).

The present study benefits from validated measures of cancer-related distress and quality of life specific to colorectal cancer and objective data on demographic and clinical characteristics. Weaknesses include the use of the IES-R to measure PTSD, which does not align as closely


Table 2. Multivariate predictors of cancer-related distress

	Cancer-related distress as a continuous variable (standardised Beta weights)	Cancer-related distress as a dichotomous variable: suspected caseness yes/no (ORs and 95% CIs)
	Adjusted <sup>3</sup>	Adjusted <sup>3</sup>
Age	–0.117 <sup>1</sup>	0.89 [0.76 to 1.06]
Fear of cancer recurrence	0.413 <sup>2</sup>	3.59 [0.64 to 20.17]
Quality of life (physical, functional and colorectal)	–0.351 <sup>2</sup>	0.87 [0.80 to 0.94] <sup>2</sup>
Perceived diagnostic delay	0.107 <sup>1</sup>	3.87 [1.20 to 12.44] <sup>1</sup>

<sup>1</sup> $p < 0.05$ .

<sup>2</sup> $p < 0.001$ .

<sup>3</sup>Adjusted for variables significant in univariate analyses.



**Figure 1.** Significant pathways between perceived diagnostic delay and cancer-related distress. Standardised coefficients (standardised coefficients from analysis using imputed data).

with DSM criteria as other measures (e.g. the PCL-C), and cannot be used to diagnose full or sub-threshold PTSD. A further weakness is the retrospective assessment of perceived diagnostic delay. It could be argued that current levels of cancer-related distress or quality of life negatively influenced people's judgments about delay. Against this argument is the lack of association between FCR and perceived delay, so there does not appear to be a global tendency to infer delay based on current distress and concerns.

A further limitation is the cross-sectional assessment of variables, so no causal inferences can be made. Future research could help clarify the relationship by measuring delay closer to the time of diagnosis and its relationship to the later development of cancer-related distress in a prospective design. Some limitations with the sample should also be noted: response rates were below 60%, the sample was less deprived than the general population of Scotland and responders were almost exclusively of white ethnicity, thereby limiting the generalizability of the results to other ethnic groups and people with lower levels of literacy.

Consistent with previous research, we observed associations between higher cancer-related distress a shorter time since diagnosis [11,15], poorer quality of life [22], and higher concerns about recurrence [19], but unlike previous research, we found no links with objective disease

outcomes, such as stage at diagnosis or treatment and distress [11]. The lack of association with stage of disease may be the result of small numbers of participants diagnosed with very late stage disease in this study. Gurevich *et al.* [28] observed that only studies including patients with advanced disease showed an association between PTSD and stage at diagnosis, while in their meta-analysis Abbey *et al.* [10] found higher rates of PTSD in studies that included patients with advanced stage disease.

Reported rates of PTSD among cancer patients vary widely across studies, and method of assessment, with symptom checklists often resulting in higher rates than those determined by clinical interview. As noted in the results, the rate of PTSD in the current study is towards the lower end of that observed in previous research [24], most probably due to the sample skew towards earlier stage at diagnosis. This suggests that in practice, rates of PTSD are quite low among colorectal cancer survivors, at least several years post-diagnosis, but rates of both partial and full PTSD in patients shortly after diagnosis remain unknown.

When it comes to experiencing cancer as a traumatic stressor, new criteria for PTSD (in DSM-5) specify that '...a life-threatening... or debilitating medical condition is not necessarily considered a traumatic event. Medical incidents that qualify as traumatic events involve sudden, catastrophic events'. The severity of cancer as a stressor

**Table 3.** Correlations between variables entered into the mediation model (imputed values given in brackets)

	Age	Perceived diagnostic delay	Fear of cancer recurrence	Quality of life (physical, functional, colorectal)
Perceived diagnostic delay	0.030 (-0.005)	1.00		
Fear of cancer recurrence	-0.252 (-0.266)	0.083 (0.082)	1.00	
Quality of life (physical, functional, colorectal)	0.152 (0.168)	-0.136 (-0.136)	-0.507 (-0.530)	1.00
Cancer-related distress	-0.260 (-0.266)	0.198 (0.184)	0.635 (0.664)	-0.609 (-0.629)

has typically been indexed by diagnostic stage and intensity of treatment [11]; however, disease stage and treatment variables did not explain associations between perceived delay and distress in the present study. Other factors associated with perceived diagnostic delay, such as intolerance of uncertainty or anxiety, may determine longer term psychological wellbeing rather than perceived diagnostic delay *per se*, or it may be due to the experiences patients go through prior to diagnosis. A UK study of patients attending hospital appointments with specialists for prostate and bladder cancer diagnostic investigations reported that 31% of patients suffered clinical levels of anxiety – which were associated with their worry about their appointment and its outcomes (i.e. cancer diagnosis), their perceived social support and their personality [40]. Differences in distress observed in the present study could relate to feelings associated with the perception of diagnostic delay *per se* (e.g. the belief there has been a medical error), or the experiences people go through that may be correlated with perceived delay, such as discovering symptoms, which may take time to be diagnosed, or situations requiring urgent medical attention (e.g. emergency admission to hospital).

This study took place prior to the introduction of nationwide screening programmes for colorectal cancer in the UK. Screen-detected disease is associated with lower perceived diagnostic delay [25], and as rates of screening uptake increase, perceived delay and any associated distress will reduce. However, groups less likely to accept the offer of screening, such as people with higher levels of deprivation and ethnic minorities [41], are more vulnerable to the development of cancer-related stress as a result of their diagnostic pathway.

Given the potential links between trauma and cancer progression [42], the need to understand and reduce factors that promote cancer-related distress in cancer survivors is a key area for future research and psychosocial intervention, and greater attention could be paid to the experiences patients go through prior to diagnosis that promote distress.

## References

1. Thomson CS, Forman D. Cancer survival in England and the influence of early diagnosis: what can we learn from recent EURO CARE results? *Brit J Cancer* 2009;**101**:S102–S109. DOI:10.1038/sj.bjc.6605399.
2. Austoker J, Bankhead C, Forbes LJ, *et al.* Interventions to promote cancer awareness and early presentation: systematic review. *Brit J Cancer* 2009;**101**:S31–S39. DOI:10.1038/sj.bjc.6605388.
3. Mansell G, Shapley M, Jordan JL, *et al.* Interventions to reduce primary care delay in cancer referral: a systematic review. *Brit J Gen Pract* 2011;**61**:e821–e835. DOI:10.3399/bjgp11X613160.
4. Miles A, Wardle J, Atkin W. Receiving a screen-detected diagnosis of cancer: the experience of participants in the UK flexible sigmoidoscopy trial. *Psycho-Oncology* 2003;**12**:784–802.
5. Green BL, Rowland JH, Krupnick JL, *et al.* Prevalence of posttraumatic stress disorder in women with breast cancer. *Psychosomatics* 1998;**39**:102–111.
6. Brocken P, van der Heijden EH, Oud KT, *et al.* Distress in suspected lung cancer patients following rapid and standard diagnostic programs: a prospective observational study. *Psycho-Oncology* 2015;**24**:433–441. DOI:10.1002/pon.3660.
7. Holland J, Watson M, Dunn J. The IPOS new International Standard of Quality Cancer Care: integrating the psychosocial domain into routine care. *Psycho-Oncology* 2011;**20**:677–680. DOI:10.1002/pon.1978.
8. Kangas M, Henry JL, Bryant RA. The course of psychological disorders in the 1st year after cancer diagnosis. *J Consult Clin Psychol* 2005;**73**:763–768.
9. Okamura M, Yamawaki S, Akechi T, *et al.* Psychiatric disorders following first breast cancer recurrence: prevalence, associated factors and relationship to quality of life. *Jpn J Clin Oncol* 2005;**35**:302–309.
10. Abbey G, Thompson SB, Hickish T, *et al.* A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder. *Psycho-Oncology* 2015;**24**:371–381. DOI:10.1002/pon.3654.

## Acknowledgements

We thank the participants of this study, patient GPs and staff at NHS National Services Scotland whose support made this study possible. A. Miles, R.J.C. Steele, N. Sevdalis and J. Wardle received a grant from the Bowel Disease Research Foundation to fund this project. N. Sevdalis' research was supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust. Sevdalis is a member of King's Improvement Science, which is part of the NIHR CLAHRC South London and comprises a specialist team of improvement scientists and senior researchers based at King's College London. Its work is funded by King's Health Partners (Guy's and St Thomas' NHS Foundation Trust, King's College Hospital NHS Foundation Trust, King's College London and South London and Maudsley NHS Foundation Trust), Guy's and St Thomas' Charity, the Maudsley Charity and the Health Foundation. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. J. Wardle is supported by Cancer Research UK. The study funder played no role in the study design, the collection, analysis and interpretation of data, the writing of the report or in the decision to submit the article for publication.

## Conflict of interest

All authors declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, with the exception of J. W. who declares that she is supported by Cancer Research UK and NS who declares that he is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust, hold an unrestricted research grant by Sanofi Pasteur and is the director of the London Training and Safety Solutions Ltd.

11. Smith MY, Redd WH, Peyser C, et al. Post-traumatic stress disorder in cancer: a review. *Psycho-Oncology* 1999;**8**:521–537.
12. Kangas M. DSM-5 trauma and stress-related disorders: implications for screening for cancer-related stress. *Front Psychiatry* 2013;**4**:122. DOI:10.3389/fpsy.2013.00122.
13. Norton TR, Manne SL, Rubin S, et al. Prevalence and predictors of psychological distress among women with ovarian cancer. *J Clin Oncol* 2004;**22**:919–926.
14. McBride CM, Clipp E, Peterson BL, et al. Psychological impact of diagnosis and risk reduction among cancer survivors. *Psycho-Oncology* 2000;**9**:418–427.
15. Sundin EC, Horowitz MJ. Horowitz's impact of event scale evaluation of 20 years of use. *Psychosom Med* 2003;**65**:870–876.
16. Risberg T, Sorbye SW, Norum J, et al. Diagnostic delay causes more psychological distress in female than in male cancer patients. *Anticancer Res* 1996;**16**:995–999.
17. Graca PM, Figueiredo AP, Fincham FD. Anxiety, depression, traumatic stress and quality of life in colorectal cancer after different treatments: a study with Portuguese patients and their partners. *Eur J Oncol Nurs* 2012;**16**:227–232.
18. Ehlers A, Clark DM. A cognitive model of posttraumatic stress disorder. *Behav Res Ther* 2000;**38**:319–345.
19. Black EK, White CA. Fear of recurrence, sense of coherence and posttraumatic stress disorder in haematological cancer survivors. *Psycho-Oncology* 2005;**14**:510–515.
20. Custers JA, Gielissen MF, Janssen SH, et al. Fear of cancer recurrence in colorectal cancer survivors. *Support Care Cancer* 2015[epub ahead of print]. DOI:10.1007/s00520-015-2808-4.
21. Marventano S, Forjaz M, Grosso G, et al. Health related quality of life in colorectal cancer patients: state of the art. *BMC Surg* 2013;**13**:S15.
22. Jacobsen PB, Widows MR, Hann DM, et al. Posttraumatic stress disorder symptoms after bone marrow transplantation for breast cancer. *Psychosom Med* 1998;**60**:366–371.
23. Shelby RA, Golden-Kreutz DM, Andersen BL. PTSD diagnoses, subsyndromal symptoms, and comorbidities contribute to impairments for breast cancer survivors. *J Trauma Stress* 2008;**21**:165–172.
24. Kangas M, Henry JL, Bryant RA. Posttraumatic stress disorder following cancer. A conceptual and empirical review. *Clin Psychol Rev* 2002;**22**:499–524.
25. Miles A, McClements PL, Steele RJ, et al. The psychological impact of a colorectal cancer diagnosis following a negative fecal occult blood test result. *Cancer Epidemiol Biomarkers Prev* 2015;**24**:1032–1038. DOI:10.1158/1055-9965.EPI-15-0004.
26. National Statistics, Scotland. Scottish Index of Multiple Deprivation [internet]. Edinburgh: The Scottish Government; 2012 [cited 2014 Oct 9]. (Available from: <http://simd.scotland.gov.uk/publication-2012>.)
27. Weiss DS, Marmar CR. In *The Impact of Events Scale – Revised. Assessing psychological trauma and PTSD*, Wilson JP, Keane TM (eds.), The Guilford Press: New York, 1997;399–411.
28. Gurevich M, Devins GM, Rodin GM. Stress response syndromes and cancer: conceptual and assessment issues. *Psychosomatics* 2002;**43**:259–281.
29. National Centre for PTSD. Impact of Event Scale - Revised (IES-R) [internet]. Washington D.C.: U.S. Department of Veterans Affairs [cited 2015 Nov 10]. (Available from: <http://www.ptsd.va.gov/professional/assessment/adult-sr/ies-r.asp>.)
30. Ward WL, Hahn EA, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. *Qual Life Res* 1999;**8**:181–195.
31. Rabin C, Leventhal H, Goodin S. Conceptualization of disease timeline predicts posttreatment distress in breast cancer patients. *Health Psychol* 2004;**23**:407–412.
32. Muthén LK, Muthén BO. *Mplus User's Guide* (6th ed.), Muthén & Muthén: Los Angeles, CA, 2010.
33. Pearman T, Yanez B, Peipert J, et al. Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. *Cancer* 2014;**120**:2902–2909.
34. Koch L, Jansen L, Brenner H, et al. Fear of recurrence and disease progression in long-term (>= 5 years) cancer survivors—a systematic review of quantitative studies. *Psycho-Oncology* 2013;**22**:1–11.
35. Geiser C. *Data Analysis with MPlus*, The Guildford Press: New York, 2013.
36. Fritz MS, MacKinnon DP. Required sample size to detect the mediated effect. *Psychol Sci* 2007;**18**:233–239.
37. Norris FH. Epidemiology of trauma: frequency and impact of different potentially traumatic events on different demographic groups. *J Consult Clin Psychol* 1992;**60**:409–418.
38. Lee-Jones C, Humphris G, Dixon R, et al. Fear of cancer recurrence – a literature review and proposed cognitive formulation to explain exacerbation of recurrence fears. *Psycho-Oncology* 1997;**6**:95–105.
39. Pita-Fernandez S, Pertega-Diaz S, Lopez-Calvino B, et al. Diagnostic and treatment delay, quality of life and satisfaction with care in colorectal cancer patients: a study protocol. *Health Qual Life Outcomes* 2013;**11**:117. DOI:10.1186/1477-7525-11-117.
40. Smith SG, Turner B, Pati J, et al. Psychological impairment in patients urgently referred for prostate and bladder cancer investigations: the role of trait emotional intelligence and perceived social support. *Support Care Cancer* 2012;**20**:699–704. DOI:10.1007/s00520-011-1129-5.
41. von Wagner C, Baio G, Raine R, et al. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. *Int J Epidemiol* 2011;**40**:712–718. DOI:10.1093/ije/dyr008.
42. Lutgendorf SK, Andersen BL. Biobehavioral approaches to cancer progression and survival: mechanisms and interventions. *Am Psychol* 2015;**70**:186–197. DOI:10.1037/a0035730.